Immunomodulatory therapy in 6427 relapsing-remitting multiple sclerosis (RRMS) patients over time under special consideration of switching to oral DMD: A retrospective data analysis

Abstract

NeuroTransData, a german neurology network of 66 physicians, has been collecting real world data in a specific MS database with more than 23.000 patients for 10 years. Longitudinal assessment of MS patients on injectable DMD who switched to oral DMD and other DMDs. RRMS-patients stable on injectable DMDs (Avonex®, Rebif®, Betaferon/Extavia® Copaxone®) for 4,3y (median) were analyzed for 6,1y (median) regarding clinical course and potential switch to oral and other treatments. 2682 (41.7%) of these 6427 patients were switched to oral DMD. The other patients stayed on their DMD for 4,6 years (median). The main reasons for switching were insufficient therapeutic effect (34,2%), side effects (18,1%) and patient’s wish (18,2%). After 1.1 years (median), 716 (26,7%) of these already switched patients were switched once again to another DMD, 123 (17,2%) switched back to their first DMD. 1735 patients (65%) remained on their first switch therapy. Observation period was 3,8 years (median). The main reason for switching from injectable to oral DMD was the therapeutic effect, followed by patient’s wish and side effects. In those patients who switched a second time, side effects were the main reason for switching. Most patients (65%) who switched from injectible to oral DMDs remained on that therapy during the observation period.